Abstract
Monkeypox virus (MPXV) of poxviridae family causes a zoonotic disease called monkeypox (Mpox). MPXV cases have a fatality ratio ranging from 0 to 11% globally and have been more prevalent in children. There are three generations of smallpox vaccines that protect against MPXV. First and second generation of the vaccinia virus (VACV) vaccine protects MPXV. However, various adverse side effects were associated with the first and second generations of vaccines. In contrast, the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) replication-incompetent vaccine shows fewer adverse effects and a significant amount of neutralizing antibodies in mammalian cells. A third-generation Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) was approved to prevent Mpox in 2019. Recently, MVA-BN-based Imvanex, Imvamune, and JYNNEOS vaccines have also been administered against MPXV. Globally, the World Health Organization (WHO) declared a global health emergency in May 2022 due to increased MPXV cases. Various computational studies have also designed a multi-epitope-based vaccine against the MPXV. In the multi-epitope-based vaccine, different epitopes like B-cell, Cytotoxic T Lymphocyte (CTL), CD8+, and CD4+ epitopes were derived from MPXV proteins. Further, these epitopes were linked with the help of various linkers to design a multi-epitope vaccine against MPXV. In summary, we have provided an overview of the current status of the vaccine against MPXV.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdi SAH, Ali A, Sayed SF et al (2022) Multi-epitope-based vaccine candidate for monkeypox: an in silico approach. Vaccines 10. https://doi.org/10.3390/VACCINES10091564
Adler H, Gould S, Hine P et al (2022) Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 22:1153–1162. https://doi.org/10.1016/S1473-3099(22)00228-6
Adnan N, Haq ZU, Malik A et al (2022) Human monkeypox virus: an updated review. Medicine (baltimore) 101:E30406. https://doi.org/10.1097/MD.0000000000030406
Aiman S, Alhamhoom Y, Ali F, Rahman N, Rastrelli L, Khan A, Farooq QUA, Ahmed A, Khan A, Li C (2022) Multi-epitope chimeric vaccine design against emerging Monkeypox virus via reverse vaccinology techniques- a bioinformatics and immunoinformatics approach. Front Immunol 13:985450. https://doi.org/10.3389/fimmu.2022.985450. PMID: 36091024; PMCID: PMC9452969
Akhtar N, Kaushik V, Grewal RK et al (2022) Immunoinformatics-aided design of a peptide based multiepitope vaccine targeting glycoproteins and membrane proteins against monkeypox virus. Viruses 14.https://doi.org/10.3390/V14112374
Al-Musa A, Chou J, LaBere B (2022) The resurgence of a neglected orthopoxvirus: Immunologic and clinical aspects of monkeypox virus infections over the past six decades. Clin Immunol 243.https://doi.org/10.1016/J.CLIM.2022.109108
Aziz S, Almajhdi FN, Waqas M et al (2022) Contriving multi-epitope vaccine ensemble for monkeypox disease using an immunoinformatics approach. Front Immunol 13. https://doi.org/10.3389/FIMMU.2022.1004804
Benhnia MR-E-I, McCausland MM, Su H-P et al (2008) Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol 82:3751–3768. https://doi.org/10.1128/JVI.02244-07
Bhattacharya M, Chatterjee S, Nag S et al (2022) Designing, characterization, and immune stimulation of a novel multi-epitopic peptide-based potential vaccine candidate against monkeypox virus through screening its whole genome encoded proteins: an immunoinformatics approach. Travel Med Infect Dis 50. https://doi.org/10.1016/J.TMAID.2022.102481
Breman JG, Nakano JH, Coffi E et al (1977) Human poxvirus disease after smallpox eradication. Am J Trop Med Hyg 26:273–281. https://doi.org/10.4269/AJTMH.1977.26.273
Bunge EM, Hoet B, Chen L et al (2022) The changing epidemiology of human monkeypox—a potential threat? A systematic review. PLoS Negl Trop Dis 16. https://doi.org/10.1371/JOURNAL.PNTD.0010141
CDC, NCIRD (2012) Selected discontinued U.S. vaccines
Chung C-S, Hsiao J-C, Chang Y-S, Chang W (1998) A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol 72:1577–1585. https://doi.org/10.1128/JVI.72.2.1577-1585.1998
Downie AW, Dumbell KR (1947) Survival of variola virus in dried exudate and crusts from smallpox patients. Lancet (London, England) 1:550–553. https://doi.org/10.1016/S0140-6736(47)91671-1
Earl PL, Americo JL, Wyatt LS et al (2004) Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428:182–185. https://doi.org/10.1038/NATURE02331
Earl PL, Americo JL, Wyatt LS et al (2008) Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A 105:10889–10894. https://doi.org/10.1073/PNAS.0804985105
Edmiston CE, Graham MB, Wilson PJ, Grahn B (2003) The monkeypox virus outbreak: reflections from the frontlines. Am J Infect Control 31:382–384. https://doi.org/10.1016/S0196-6553(03)00652-7
Erez N, Achdout H, Milrot E et al (2019) Diagnosis of Imported Monkeypox, Israel, 2018. Emerg Infect Dis 25:980–983. https://doi.org/10.3201/EID2505.190076
FDA, CDER, PURDIEF (2013) Guidance for industry labeling for human prescription drug and biological products-implementing the PLR Content and format requirements guidance for industry labeling for human prescription drug and biological products-implementing the PLR content and format requirements labeling contains nonbinding recommendations
Formenty P, Muntasir MO, Damon I et al (2010) Human monkeypox outbreak caused by novel virus belonging to Congo Basin clade, Sudan, 2005. Emerg Infect Dis 16:1539–1545. https://doi.org/10.3201/EID1610.100713
Frey SE, Newman FK, Kennedy JS et al (2009) Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 27:1637–1644. https://doi.org/10.1016/J.VACCINE.2008.11.079
Frey SE, Wald A, Edupuganti S et al (2015) Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine 33:5225–5234. https://doi.org/10.1016/J.VACCINE.2015.06.075
Hayat C, Shahab M, Khan SA et al (2022) Design of a novel multiple epitope-based vaccine: an immunoinformatics approach to combat monkeypox. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2022.2141887
Heymann DL, Szczeniowski M, Esteves K (1998) Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull 54:693–702. https://doi.org/10.1093/OXFORDJOURNALS.BMB.A011720
Hsiao J-C, Chung C-S, Chang W (1998) Cell surface proteoglycans are necessary for A27L protein-mediated cell fusion: identification of the N-terminal region of A27L protein as the glycosaminoglycan-binding domain. J Virol 72:8374–8379. https://doi.org/10.1128/JVI.72.10.8374-8379.1998
Hsiao J-C, Chung C-S, Chang W (1999) Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 73:8750–8761. https://doi.org/10.1128/JVI.73.10.8750-8761.1999
Huhn GD, Bauer AM, Yorita K et al (2005) Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis 41:1742–1751. https://doi.org/10.1086/498115
Hung YP, Lee CC, Lee JC et al (2022) A brief on new waves of monkeypox and vaccines and antiviral drugs for monkeypox. J Microbiol Immunol Infect 55:795–802. https://doi.org/10.1016/J.JMII.2022.08.016
Jezek Z, Arita I, Mutombo M et al (1986) Four generations of probable person-to-person transmission of human monkeypox. Am J Epidemiol 123:1004–1012. https://doi.org/10.1093/OXFORDJOURNALS.AJE.A114328
Ježek Z, Szczeniowski M, Paluku KM, Mutombo M (1987) Human monkeypox: clinical features of 282 patients. J Infect Dis 156:293–298. https://doi.org/10.1093/INFDIS/156.2.293
Kugelman JR, Johnston SC, Mulembakani PM et al (2014) Genomic variability of monkeypox virus among humans, Democratic Republic of the Congo. Emerg Infect Dis 20:232–239. https://doi.org/10.3201/EID2002.130118
Kumar N, Acharya A, Gendelman HE, Byrareddy SN (2022) The 2022 outbreak and the pathobiology of the monkeypox virus. J Autoimmun 131. https://doi.org/10.1016/J.JAUT.2022.102855
Lalezari JP, Drew WL, Glutzer E et al (1995) (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 171:788–796. https://doi.org/10.1093/INFDIS/171.4.788
Ligon BL (2004) Monkeypox: a review of the history and emergence in the Western hemisphere. Semin Pediatr Infect Dis 15:280–287. https://doi.org/10.1053/j.spid.2004.09.001
Likos AM, Sammons SA, Olson VA et al (2005) A tale of two clades: monkeypox viruses. J Gen Virol 86:2661–2672. https://doi.org/10.1099/VIR.0.81215-0
Lin C-L, Chung C-S, Heine HG, Chang W (2000) Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol 74:3353–3365. https://doi.org/10.1128/JVI.74.7.3353-3365.2000
Lum FM, Torres-Ruesta A, Tay MZ et al (2022) Monkeypox: disease epidemiology, host immunity and clinical interventions. Nat Rev Immunol 22:597–613. https://doi.org/10.1038/S41577-022-00775-4
Luong Nguyen LB, Ghosn J, Durier C, et al (2022) A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox. Nat Med 28. https://doi.org/10.1038/D41591-022-00077-1
Marennikova SS, Seluhina EM, Mal’ceva NN, et al (1972) Isolation and properties of the causal agent of a new variola-like disease (monkeypox) in man. Bull World Health Organ 46:599
Marriott KA, Parkinson CV, Morefield SI et al (2008) Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 26:581–588. https://doi.org/10.1016/J.VACCINE.2007.10.063
Mbala PK, Huggins JW, Riu-Rovira T et al (2017) Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo. J Infect Dis 216:824–828. https://doi.org/10.1093/INFDIS/JIX260
McFadden G (2005) Poxvirus tropism. Nat Rev Microbiol 3:201–213. https://doi.org/10.1038/NRMICRO1099
Molero-Abraham M, Glutting JP, Flower DR, et al (2015) EPIPOX: immunoinformatic characterization of the shared T-Cell epitome between variola virus and related pathogenic orthopoxviruses. J Immunol Res 2015.https://doi.org/10.1155/2015/738020
Nalca A, Zumbrun EE (2010) ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther 4:71–79. https://doi.org/10.2147/DDDT.S3687
Nguyen PY, Ajisegiri WS, Costantino V et al (2021) Reemergence of human monkeypox and declining population immunity in the context of urbanization, Nigeria, 2017–2020. Emerg Infect Dis 27:1007–1014. https://doi.org/10.3201/EID2704.203569
Pittman PR, Hahn M, Lee HS et al (2019) Phase 3 efficacy trial of Modified Vaccinia Ankara as a vaccine against smallpox. N Engl J Med 381:1897–1908. https://doi.org/10.1056/NEJMOA1817307
Rimoin AW, Mulembakani PM, Johnston SC et al (2010) Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A 107:16262–16267. https://doi.org/10.1073/PNAS.1005769107
Russo AT, Grosenbach DW, Chinsangaram J et al (2021) An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther 19:331–344. https://doi.org/10.1080/14787210.2020.1819791
Saxena SK, Ansari S, Maurya VK et al (2023) Re-emerging human monkeypox: a major public-health debacle. J Med Virol 95. https://doi.org/10.1002/JMV.27902
Shantier SW, Mustafa MI, Abdelmoneim AH et al (2022) Novel multi epitope-based vaccine against monkeypox virus: vaccinomic approach. Sci Rep 12. https://doi.org/10.1038/S41598-022-20397-Z
Shchelkunov SN, Totmenin AV, Babkin IV et al (2001) Human monkeypox and smallpox viruses: genomic comparison. FEBS Lett 509:66–70. https://doi.org/10.1016/S0014-5793(01)03144-1
Shchelkunov SN, Totmenin AV, Safronov PF et al (2002) Analysis of the monkeypox virus genome. Virology 297:172–194. https://doi.org/10.1006/viro.2002.1446
Smith GL, Vanderplasschen A, Law M (2002) The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83:2915–2931. https://doi.org/10.1099/0022-1317-83-12-2915
Suleman M, Rashid F, Ali S et al (2022) Immunoinformatic-based design of immune-boosting multiepitope subunit vaccines against monkeypox virus and validation through molecular dynamics and immune simulation. Front Immunol 13. https://doi.org/10.3389/FIMMU.2022.1042997
Swetha RG, Basu S, Ramaiah S, Anbarasu A (2022) Multi-epitope vaccine for monkeypox using pan-genome and reverse vaccinology approaches. Viruses 14.https://doi.org/10.3390/V14112504
Townsend MB, Keckler MS, Patel N et al (2013) Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations. J Virol 87:900–911. https://doi.org/10.1128/JVI.02089-12
Ullah A, Shahid FA, Haq MU et al (2022) An integrative reverse vaccinology, immunoinformatic, docking and simulation approaches towards designing of multi-epitopes based vaccine against monkeypox virus. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2022.2125441
Vanderplasschen A, Hollinshead M, Smith GL (1998) Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol 79(Pt 4):877–887. https://doi.org/10.1099/0022-1317-79-4-877
Volz A, Sutter G (2017) Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res 97:187–243. https://doi.org/10.1016/BS.AIVIR.2016.07.001
Walsh SR, Wilck MB, Dominguez DJ et al (2013) Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis 207:1888–1897. https://doi.org/10.1093/INFDIS/JIT105
Wilson ME, Hughes JM, McCollum AM, Damon IK (2014) Human monkeypox. Clin Infect Dis 58:260–267. https://doi.org/10.1093/CID/CIT703
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rastogi, A., Kumar, M. (2024). Current Status of Vaccine Development for Monkeypox Virus. In: Rezaei, N. (eds) Poxviruses. Advances in Experimental Medicine and Biology, vol 1451. Springer, Cham. https://doi.org/10.1007/978-3-031-57165-7_18
Download citation
DOI: https://doi.org/10.1007/978-3-031-57165-7_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-57164-0
Online ISBN: 978-3-031-57165-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)